high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer research hub

A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative

This study looks at two medicines, Lenvatinib and Keytruda, for women with a type of womb-neck cancer that is advanced or hasn't responded well to usual treatments. It's a Phase II study, meaning researchers are checking if these medicines together are a good option.